<DOC>
	<DOCNO>NCT00945035</DOCNO>
	<brief_summary>This study establish bioequivalence 20 % , mill , roller compaction final market image ( FMI ) etoricoxib tablet 30 % unmilled , roller compaction ( UMC ) etoricoxib tablet .</brief_summary>
	<brief_title>Study Bioequivalence 20 % 30 % Etoricoxib Tablet Formulations ( 0663-070 )</brief_title>
	<detailed_description />
	<mesh_term>Etoricoxib</mesh_term>
	<criteria>Subject good health Subject agree follow study guideline Subject smoker Subject history adverse reaction cause NSAIDs allergies/intolerance NSAIDs Subject situation condition/disease may interfere optimal participation study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>